Novo Nordisk Shareholders Weigh Buyback Flow Against a Clouded US Outlook

Novo Nordisk is still writing cheques to its own shareholders even as doubts gather over its American business. The Danish drugmaker confirmed fresh purchases under a repurchase programme capped at DKK 15 billion on Monday, a reminder that capital returns remain in full swing while the operating picture looks less certain.

The twelve-month scheme, which got under way on 4 February, has simply been ticking along. Monday's disclosure neither unveiled a new programme nor lifted the existing ceiling — it was a progress note, nothing more. That distinction matters: buybacks speak to how Novo Nordisk deploys its cash, not to how its medicines are selling. Investors who blur the two risk mistaking a capital-allocation decision for an improvement in the business itself.

A Broker's Warning on Ozempic

On the operating side, BMO Capital's Evan Seigerman struck a cautious note on 12 October, trimming his price target to $40 from $47 while keeping a "Market Perform" rating. He pointed to a punishing year-on-year comparison and eroding US market share, both of which he expects could weigh on Ozempic revenue in the third quarter of 2026. The benchmark he has in mind is the third quarter of 2025 — and his view is a forecast, not reported figures.

CagriSema's Nuance

Offsetting some of that gloom is the detailed readout on CagriSema, which Novo Nordisk published on Tuesday. The post-hoc analysis of the Phase III REDEFINE 1 trial covered 2,309 women with overweight or obesity and, assuming treatment adherence, showed an average weight loss of 25.0% after 68 weeks. The placebo arm managed 3.0%. Reuters framed the findings as possible support for CagriSema's case as a successor to Wegovy.

The same dataset, however, carries caveats that deserve equal billing. It is an exploratory look back at a completed study, and CagriSema is not approved. The full trial, moreover, delivered a 22.7% reduction — short of the company's own 25% goal. Tuesday's subgroup breakdown should not be confused with that headline figure.

Menopause as a Lens, Not a Cause

What the new analysis adds is a finer-grained view by menopausal stage. Women who had not yet reached menopause averaged a 26.7% reduction. Those in the transition phase recorded 24.8%, and those past menopause 23.1%. Each cohort thus came in below the one preceding it, while all three stayed well clear of the placebo result.

Novo Nordisk is careful to frame this as an observation rather than a causal claim: the breakdown does not establish that menopausal status itself drove the differences. Nor should any single subgroup be read as the overall average.

Two Questions, One Stock

The buyback and the CagriSema data answer entirely separate questions, and neither on its own neutralises the US pressures BMO has flagged. On the valuation side, Oddo BHF raised its target for Novo Nordisk to DKK 305 from DKK 221 on Tuesday while leaving its rating at neutral — a higher number without a warmer recommendation. No link between that move and the CagriSema release has been established.

For shareholders, the yardstick stays the same: whether Novo Nordisk can contain the operational strain in the US and turn an experimental product's promise into durable revenue. Capital returns and clinical readouts each tell part of that story — just not the same part.